Cargando…
Splicing regulatory factors in breast cancer hallmarks and disease progression
By regulating transcript isoform expression levels, alternative splicing provides an additional layer of protein control. Recent studies show evidence that cancer cells use different splicing events to fulfill their requirements in order to develop, progress and metastasize. However, there has been...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800274/ https://www.ncbi.nlm.nih.gov/pubmed/31666932 http://dx.doi.org/10.18632/oncotarget.27215 |
_version_ | 1783460416954826752 |
---|---|
author | Koedoot, Esmee Wolters, Liesanne van de Water, Bob Le Dévédec, Sylvia E. |
author_facet | Koedoot, Esmee Wolters, Liesanne van de Water, Bob Le Dévédec, Sylvia E. |
author_sort | Koedoot, Esmee |
collection | PubMed |
description | By regulating transcript isoform expression levels, alternative splicing provides an additional layer of protein control. Recent studies show evidence that cancer cells use different splicing events to fulfill their requirements in order to develop, progress and metastasize. However, there has been less attention for the role of the complex catalyzing the complicated multistep splicing reaction: the spliceosome. The spliceosome consists of multiple sub-complexes in total comprising 244 proteins or splice factors and 5 associated RNA molecules. Here we discuss the role of splice factors in the oncogenic processes tumors cells need to fulfill their oncogenic properties (the so-called the hallmarks of cancer). Despite the fact that splice factors have been investigated only recently, they seem to play a prominent role in already five hallmarks of cancer: angiogenesis, resisting cell death, sustaining proliferation, deregulating cellular energetics and invasion and metastasis formation by affecting major signaling pathways such as epithelial-to-mesenchymal transition, the Warburg effect, DNA damage response and hormone receptor dependent proliferation. Moreover, we could relate expression of representative genes of four other hallmarks (enabling replicative mortality, genomic instability, avoiding immune destruction and evading growth suppression) to splice factor levels in human breast cancer tumors, suggesting that also these hallmarks could be regulated by splice factors. Since many splice factors are involved in multiple hallmarks of cancer, inhibiting splice factors might provide a new layer of oncogenic control and a powerful method to combat breast cancer progression. |
format | Online Article Text |
id | pubmed-6800274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-68002742019-10-30 Splicing regulatory factors in breast cancer hallmarks and disease progression Koedoot, Esmee Wolters, Liesanne van de Water, Bob Le Dévédec, Sylvia E. Oncotarget Review By regulating transcript isoform expression levels, alternative splicing provides an additional layer of protein control. Recent studies show evidence that cancer cells use different splicing events to fulfill their requirements in order to develop, progress and metastasize. However, there has been less attention for the role of the complex catalyzing the complicated multistep splicing reaction: the spliceosome. The spliceosome consists of multiple sub-complexes in total comprising 244 proteins or splice factors and 5 associated RNA molecules. Here we discuss the role of splice factors in the oncogenic processes tumors cells need to fulfill their oncogenic properties (the so-called the hallmarks of cancer). Despite the fact that splice factors have been investigated only recently, they seem to play a prominent role in already five hallmarks of cancer: angiogenesis, resisting cell death, sustaining proliferation, deregulating cellular energetics and invasion and metastasis formation by affecting major signaling pathways such as epithelial-to-mesenchymal transition, the Warburg effect, DNA damage response and hormone receptor dependent proliferation. Moreover, we could relate expression of representative genes of four other hallmarks (enabling replicative mortality, genomic instability, avoiding immune destruction and evading growth suppression) to splice factor levels in human breast cancer tumors, suggesting that also these hallmarks could be regulated by splice factors. Since many splice factors are involved in multiple hallmarks of cancer, inhibiting splice factors might provide a new layer of oncogenic control and a powerful method to combat breast cancer progression. Impact Journals LLC 2019-10-15 /pmc/articles/PMC6800274/ /pubmed/31666932 http://dx.doi.org/10.18632/oncotarget.27215 Text en Copyright: © 2019 Koedoot et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Koedoot, Esmee Wolters, Liesanne van de Water, Bob Le Dévédec, Sylvia E. Splicing regulatory factors in breast cancer hallmarks and disease progression |
title | Splicing regulatory factors in breast cancer hallmarks and disease progression |
title_full | Splicing regulatory factors in breast cancer hallmarks and disease progression |
title_fullStr | Splicing regulatory factors in breast cancer hallmarks and disease progression |
title_full_unstemmed | Splicing regulatory factors in breast cancer hallmarks and disease progression |
title_short | Splicing regulatory factors in breast cancer hallmarks and disease progression |
title_sort | splicing regulatory factors in breast cancer hallmarks and disease progression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800274/ https://www.ncbi.nlm.nih.gov/pubmed/31666932 http://dx.doi.org/10.18632/oncotarget.27215 |
work_keys_str_mv | AT koedootesmee splicingregulatoryfactorsinbreastcancerhallmarksanddiseaseprogression AT woltersliesanne splicingregulatoryfactorsinbreastcancerhallmarksanddiseaseprogression AT vandewaterbob splicingregulatoryfactorsinbreastcancerhallmarksanddiseaseprogression AT ledevedecsylviae splicingregulatoryfactorsinbreastcancerhallmarksanddiseaseprogression |